Labmark Limited – Tanzania Clinical Research and IVD CRO

Experience

Labmark Limited is a Tanzania-headquartered Contract Research Organization specialising in in-vitro diagnostics, medical devices, infectious-disease research, epidemiology and real-world evidence.
We provide end-to-end study delivery covering country and site feasibility, patient-pathway assessment, protocol and operational planning, ethics and regulatory submissions, site selection and activation, project management, site management, clinical monitoring, data management, specimen workflow design, laboratory coordination, quality oversight, medical writing and study close-out.
Our experience includes multi-site diagnostic studies, clinical performance evaluations, specimen-collection studies and epidemiological research delivered through public and private healthcare facilities and qualified laboratory partners.
Our team applies ICH-GCP, GCLP, ALCOA+ data-integrity principles and applicable medical-device and IVD standards. We combine local knowledge of Tanzanian health systems with international clinical research and regulatory requirements.
Labmark’s distinguishing capability is its integrated operating model. Sponsors work through one accountable Tanzania-based partner coordinating clinical sites, laboratories, regulatory activities, logistics, monitoring, quality and data delivery.

Research interests

Labmark works with international IVD and medical-device manufacturers, global and regional CROs, site-management organisations, clinical laboratories, public and private hospitals, universities, research institutions and specialist consultants.
Our operating model combines a Tanzania-based core research team with qualified clinical and laboratory partners across multiple locations. Partners are selected against protocol-specific requirements for patient access, investigator capability, laboratory capacity, specimen handling, regulatory readiness and data quality.
Labmark can establish project-specific partnerships for clinical performance studies, diagnostic accuracy studies, epidemiological research, real-world evidence generation and post-market studies. Named client and sponsor relationships can be disclosed where confidentiality arrangements permit.

Disease areas

• Cholera
• COVID-19
• Dengue
• Enteric diseases
• Helminths
• HIV
• Neglected Tropical Diseases (NTDs)
• Respiratory Diseases
• Sexually Transmitted Diseases (STDs)
• TB
• Zika

Labmark’s primary focus is infectious-disease and syndrome-based diagnostic research. Relevant areas include tuberculosis, HIV, sexually transmitted infections, malaria, acute febrile illness, enteric infections and respiratory infections. Our capabilities include IVD clinical performance evaluation, diagnostic accuracy studies, specimen-collection studies, clinical and laboratory workflow studies, epidemiology, real-world evidence and post-market performance follow-up. We can expand into other disease areas through qualified partner sites selected according to protocol-specific patient availability, clinical pathways, investigator experience and laboratory requirements.

Other information

Labmark helps sponsors move from reported site capability to evidence-based study feasibility.
Our feasibility approach assesses real patient pathways, referral patterns, protocol eligibility, recruitment conversion, specimen availability, laboratory workflows, staffing, equipment, power, storage, transport and data traceability.
Before activation, we can conduct patient-record reviews, facility assessments, staff and referral mapping, laboratory-capability verification and end-to-end workflow simulations.
During study conduct, Labmark provides central project oversight, risk-based monitoring, quality-control tracking, issue escalation, corrective and preventive action management, documentation oversight and sponsor reporting.
This approach is designed for sponsors requiring reliable in-country execution rather than stand-alone advisory support.